Clearside Biomedical (CLSD) Projected to Post Quarterly Earnings on Thursday

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.20 million for the quarter.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.03. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.27 million. On average, analysts expect Clearside Biomedical to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Stock Performance

Shares of NASDAQ CLSD traded down $0.02 during trading on Tuesday, hitting $0.87. 17,031 shares of the company traded hands, compared to its average volume of 344,307. The business's fifty day moving average is $0.88 and its 200 day moving average is $0.96. The firm has a market capitalization of $67.31 million, a price-to-earnings ratio of -1.94 and a beta of 2.11. Clearside Biomedical has a fifty-two week low of $0.70 and a fifty-two week high of $1.65.

Analysts Set New Price Targets

Several research firms have recently commented on CLSD. Needham & Company LLC restated a "buy" rating and set a $4.00 price objective on shares of Clearside Biomedical in a report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Monday, March 31st. StockNews.com upgraded shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a report on Friday, April 25th. Finally, Chardan Capital reissued a "buy" rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $5.25.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.